Treatment of anxiety disorders

Anxiety disorders (generalized anxiety disorder, panic disorder/agoraphobia, social anxiety disorder, and others) are the most prevalent psychiatric disorders, and are associated with a high burden of illness. Anxiety disorders are often underrecognized and undertreated in primary care. Treatment is indicated when a patient shows marked distress or suffers from complications resulting from the disorder. The treatment recommendations given in this article are based on guidelines, meta-analyses, and systematic reviews of randomized controlled studies. Anxiety disorders should be treated with psychological therapy, pharmacotherapy, or a combination of both. Cognitive behavioral therapy can be regarded as the psychotherapy with the highest level of evidence. First-line drugs are the selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Benzodiazepines are not recommended for routine use. Other treatment options include pregabalin, tricyclic antidepressants, buspirone, moclobemide, and others. After remission, medications should be continued for 6 to 12 months. When developing a treatment plan, efficacy, adverse effects, interactions, costs, and the preference of the patient should be considered.

[1]  S. Hamilton,et al.  Use of Antidepressants During Pregnancy?: What to Consider when Weighing Treatment with Antidepressants Against Untreated Depression , 2016, Maternal and Child Health Journal.

[2]  H. Volz,et al.  Efficacy of Silexan in mixed anxiety–depression – A randomized, placebo-controlled trial , 2016, European Neuropsychopharmacology.

[3]  Hans Eriksson,et al.  Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial , 2011, International clinical psychopharmacology.

[4]  Dan J Stein,et al.  Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. , 2014, The Journal of clinical psychiatry.

[5]  D. Baldwin,et al.  Clinically relevant drug interactions in anxiety disorders , 2012, Human psychopharmacology.

[6]  K. Dimopoulos,et al.  Antidepressant use in pregnancy and the risk of cardiac defects. , 2014, The New England journal of medicine.

[7]  H. Gross,et al.  Use of benzodiazepines in anxiety disorders. , 1993, The New England journal of medicine.

[8]  M. Hamilton The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[9]  E. Rüther,et al.  The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. , 2000, Pharmacopsychiatry.

[10]  F. Goodwin,et al.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. , 1993, Archives of general psychiatry.

[11]  J. Strawn,et al.  Pharmacologic Treatment of Pediatric Anxiety Disorders , 2016, Current Treatment Options in Psychiatry.

[12]  B. Daniels,et al.  Controlled Comparison of Computer-Aided Vicarious Exposure Versus Live Exposure in the Treatment of Spider Phobia , 2000 .

[13]  P. Cuijpers,et al.  Scaling-up treatment of depression and anxiety: a global return on investment analysis. , 2016, The lancet. Psychiatry.

[14]  S. Cummings,et al.  An Internet-Based Randomized, Placebo-Controlled Trial of Kava and Valerian for Anxiety and Insomnia , 2005, Medicine.

[15]  Dan J Stein,et al.  Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.

[16]  P. Schulz,et al.  A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. , 2008, Psychopharmacology bulletin.

[17]  A. Serretti,et al.  Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis , 2009, Journal of clinical psychopharmacology.

[18]  W. Gaebel,et al.  Erratum zu: Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul „Psychische Gesundheit“ (DEGS1-MH) , 2015, Der Nervenarzt.

[19]  T. Mackenzie,et al.  Prevalence and treatment of mental disorders. , 2005, The New England journal of medicine.

[20]  B. Bandelow,et al.  Epidemiology of anxiety disorders in the 21st century , 2015, Dialogues in clinical neuroscience.

[21]  J. Angst,et al.  Social phobia. , 1995, European archives of psychiatry and clinical neuroscience.

[22]  Dan J. Stein,et al.  Pharmacotherapy for anxiety disorders in children and adolescents ( Review ) , 2022 .

[23]  D. Stein,et al.  Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study , 2017, European Neuropsychopharmacology.

[24]  K. Rickels,et al.  The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients , 1998, Psychological Medicine.

[25]  M. Höfler,et al.  [Mental disorders in the general population : Study on the health of adults in Germany and the additional module mental health (DEGS1-MH)]. , 2014, Der Nervenarzt.

[26]  M. Iyo,et al.  Cognitive Behavioral Therapy for Patients with Social Anxiety Disorder Who Remain Symptomatic following Antidepressant Treatment: A Randomized, Assessor-Blinded, Controlled Trial , 2016, Psychotherapy and Psychosomatics.

[27]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[28]  J. Lindesay,et al.  The Epidemiology of Depression and Anxiety , 2010 .

[29]  A. Gumley,et al.  Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. , 2005, Health technology assessment.

[30]  G. Rubio,et al.  Generalized anxiety disorder: a 40‐year follow‐up study , 2007, Acta psychiatrica Scandinavica.

[31]  A. Balkom,et al.  Late-life Anxiety Disorders: A Review , 2011, Current psychiatry reports.

[32]  D. Baldwin,et al.  The separation of adult separation anxiety disorder , 2016, CNS Spectrums.

[33]  L. Taylor,et al.  St John's wort versus placebo in obsessive–compulsive disorder: results from a double-blind study , 2005, International clinical psychopharmacology.

[34]  D. Smith,et al.  Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse. , 1990, Journal of psychiatric research.

[35]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[36]  K. Manassis,et al.  The use of medication in selective mutism: a systematic review , 2016, European Child & Adolescent Psychiatry.

[37]  U. Lepola,et al.  Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. , 2003, The Journal of clinical psychiatry.

[38]  Hans-Jürgen Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[39]  M. Beutel,et al.  The German guidelines for the treatment of anxiety disorders , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[40]  P Tyrer,et al.  Benzodiazepine Dependence , 1993, Drug safety.

[41]  H. Möller,et al.  Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. , 2014, The international journal of neuropsychopharmacology.

[42]  R. Teschke,et al.  Kava in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study , 2013, Journal of clinical psychopharmacology.

[43]  S. Woods,et al.  Early coadministration of clonazepam with sertraline for panic disorder. , 2001, Archives of general psychiatry.

[44]  H. Möller,et al.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 1: general aspects and paradigmatic discussion of depressive disorders , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[45]  S. Kennedy,et al.  Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study , 2004, International clinical psychopharmacology.

[46]  J. López-Ibor,et al.  What can be learnt from the natural history of anxiety disorders? , 2007, European Psychiatry.

[47]  B. Penninx,et al.  Adherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis. , 2009, General hospital psychiatry.

[48]  H. Eriksson,et al.  A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder , 2011, Journal of clinical psychopharmacology.

[49]  D. Brent,et al.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. , 2007, The American journal of psychiatry.

[50]  R. Kessler,et al.  12‐Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.

[51]  S. Kellett,et al.  Efficacy of Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults: Systematic Review, Meta-Analysis, and Meta-Regression. , 2016, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[52]  M. Höfler,et al.  Generalized anxiety and depression in primary care: prevalence, recognition, and management. , 2002, The Journal of clinical psychiatry.

[53]  A. Gamma,et al.  The generalized anxiety spectrum: prevalence, onset, course and outcome , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[54]  D. Greenblatt,et al.  Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. , 1990, Archives of general psychiatry.

[55]  M. Beutel,et al.  The diagnosis of and treatment recommendations for anxiety disorders. , 2014, Deutsches Arzteblatt international.

[56]  J. Rosenbaum,et al.  Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. , 1993, The American journal of psychiatry.

[57]  D. Wedekind,et al.  A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[58]  M. Lindquist,et al.  Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system , 1997, European Journal of Clinical Pharmacology.

[59]  D. Stein,et al.  Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. , 2002, Archives of general psychiatry.

[60]  Dan J Stein,et al.  How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database , 2009, Human psychopharmacology.

[61]  K. Rickels Benzodiazepines in the treatment of anxiety. , 1982, American journal of psychotherapy.

[62]  J. Benjamin,et al.  Double-blind placebo-controlled pilot study of paroxetine for specific phobia , 2000, Psychopharmacology.

[63]  H. Möller,et al.  The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice , 2016, European Archives of Psychiatry and Clinical Neuroscience.

[64]  M. Schubert-Zsilavecz,et al.  Comparison of German St. John's wort products according to hyperforin and total hypericin content. , 2001, Journal of the American Pharmaceutical Association.

[65]  D. Wedekind,et al.  Efficacy of treatments for anxiety disorders: a meta-analysis , 2015, International clinical psychopharmacology.

[66]  R. Emsley,et al.  Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. , 2009, The Journal of clinical psychiatry.

[67]  Georgina James,et al.  Cognitive behavioural therapy for anxiety disorders in children and adolescents. , 2015, The Cochrane database of systematic reviews.

[68]  J. Bobes,et al.  Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. , 2010, The international journal of neuropsychopharmacology.

[69]  D. A. Spiegel Psychological strategies for discontinuing benzodiazepine treatment. , 1999, Journal of clinical psychopharmacology.

[70]  J. Davidson,et al.  Kava in generalized anxiety disorder: three placebo-controlled trials , 2006, International clinical psychopharmacology.

[71]  S. Kasper,et al.  Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial , 2015, European Neuropsychopharmacology.

[72]  J. McKenzie,et al.  Newer generation antidepressants for depressive disorders in children and adolescents. , 2012, The Cochrane database of systematic reviews.

[73]  D. Nutt,et al.  Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[74]  Ø. Langsrud,et al.  A randomized controlled trial of a home and school-based intervention for selective mutism - defocused communication and behavioural techniques. , 2014, Child and adolescent mental health.

[75]  R. Kessler,et al.  Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States , 2012, International journal of methods in psychiatric research.

[76]  B. Bandelow Comparison of the DSM–5 and ICD–10: panic and other anxiety disorders , 2017, CNS Spectrums.

[77]  D. Baldwin,et al.  The use of antidepressants in clinical practice: focus on agomelatine , 2010, Human psychopharmacology.

[78]  Xiaogang Li,et al.  The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis , 2016, Neuropsychiatric disease and treatment.

[79]  Paul McCrone,et al.  Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology , 2014, Journal of psychopharmacology.

[80]  J. Walkup,et al.  Treatment of separation, generalized, and social anxiety disorders in youths. , 2014, The American journal of psychiatry.

[81]  M. Boyle,et al.  The use of waitlists as control conditions in anxiety disorders research. , 2016, Journal of psychiatric research.

[82]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[83]  E. Rüther,et al.  Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. , 1998, The American journal of psychiatry.

[84]  S. Stahl Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. , 2002, The Journal of clinical psychiatry.

[85]  Dan J Stein,et al.  Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. , 2012, The Journal of clinical psychiatry.

[86]  H. Woelk,et al.  A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[87]  G. Chouinard,et al.  Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. , 1999, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[88]  S. Montgomery,et al.  A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. , 2005, The Journal of clinical psychiatry.

[89]  Jordi Alonso,et al.  Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). , 2007, The Journal of clinical psychiatry.

[90]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[91]  Satish Iyengar,et al.  Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. , 2008, The New England journal of medicine.

[92]  J. Bradwejn Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[93]  J. Mann,et al.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. , 2007, The American journal of psychiatry.

[94]  D. Nutt,et al.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[95]  J. Os,et al.  The size and burden of mental disorders and other disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.

[96]  A. Scholey,et al.  Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence , 2011, European Neuropsychopharmacology.

[97]  Harold Alan Pincus,et al.  Prevalence and treatment of mental disorders, 1990 to 2003. , 2005, The New England journal of medicine.

[98]  D. Baldwin,et al.  Pregabalin for the treatment of generalized anxiety disorder: an update , 2013, Neuropsychiatric disease and treatment.

[99]  F. Oyebode,et al.  Psychotropics in pregnancy: safety and other considerations. , 2012, Pharmacology & therapeutics.

[100]  H. Möller,et al.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care , 2012, International journal of psychiatry in clinical practice.

[101]  V. Starcevic The reappraisal of benzodiazepines in the treatment of anxiety and related disorders , 2014, Expert review of neurotherapeutics.

[102]  J. Leite,et al.  Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo‐controlled pilot study , 2002, Phytotherapy research : PTR.

[103]  D. Greenblatt,et al.  Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. , 1990, Archives of general psychiatry.

[104]  J. Piacentini,et al.  Integrated Behavior Therapy for Selective Mutism: a randomized controlled pilot study. , 2013, Behaviour research and therapy.

[105]  J. Erickson,et al.  Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial , 2008, European Neuropsychopharmacology.